Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
Investor's Business Daily on MSN1d
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy PointsNetflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a recent press release, Lilly is now offering a four-week supply of 2.5 ...
Eli Lilly (NYSE: LLY) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback